Vaccine 2007, 25:6842–6844.PubMedCrossRef 13. Andersen P, Doherty TM: The success and failure of BCG – implications for a novel tuberculosis vaccine. Nat Rev Microbiol 2005,

3:656–662.PubMedCrossRef 14. Antas PR, Castello-Branco LR: New vaccines against tuberculosis: lessons learned from BCG immunisation in Brazil. Trans R Soc Trop Med Hyg 2008, 102:628–630.PubMedCrossRef 15. Castillo-Rodal AI, Castanon-Arreola M, Hernandez-Pando R, Calva JJ, Sada-Diaz E, Lopez-Vidal Y: Mycobacterium bovis BCG substrains confer different levels of protection against Mycobacterium tuberculosis BTK screening infection in a BALB/c model of progressive pulmonary tuberculosis. Infect Immun 2006, 74:1718–1724.PubMedCrossRef 16. Rodriguez-Alvarez M, Mendoza-Hernandez G, Encarnacion S, Calva JJ, Lopez-Vidal Y: Phenotypic differences between BCG vaccines at the proteome level. Tuberculosis (Edinb) 2009, ARRY-438162 manufacturer 89:126–135.CrossRef 17. Brandt L, Feino Cunha J, Weinreich Olsen A, Chilima B, Hirsch P, Appelberg R, Andersen P: Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect Immun 2002, 70:672–678.PubMedCrossRef 18. Colditz GA, Brewer TF, Berkey CS, Wilson

ME, Burdick E, Fineberg HV, Mosteller F: Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994, 271:698–702.PubMedCrossRef 19. Fine PE, Carneiro IA, Milstien JB, Clements CJ: Issues Relating to the Use of BCG in Immunisation Programmes. A discussion document. Geneva: World Health Organisation. Department of Vaccines and Biologicals; 1999:1–45. 20. Trajkovic V, Natarajan K, Sharma P: Immunomodulatory action of mycobacterial secretory proteins. Microbes Infect 2004, 6:513–519.PubMedCrossRef 21. Malen H, Berven FS, Fladmark KE, Wiker HG: Comprehensive analysis of exported proteins from Mycobacterium tuberculosis H37Rv. Proteomics 2007, 7:1702–1718.PubMedCrossRef 22. Hubbard RD, Flory CM, Collins FM: Cediranib (AZD2171) Immunization of mice with mycobacterial

culture filtrate proteins. Clin Exp Immunol 1992, 87:94–98.PubMedCrossRef 23. Andersen P: Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect Immun 1994, 62:2536–2544.PubMed 24. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S: Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA 2000, 97:13853–13858.PubMedCrossRef 25. Kamath AT, Rochat AF, Valenti MP, Agger EM, Lingnau K, Andersen P, Lambert PH, Siegrist CA: Adult-like anti-mycobacterial T cell and in vivo dendritic cell responses following neonatal immunization with Ag85B-ESAT-6 in the IC31 adjuvant. PLoS One 2008, 3:e3683.PubMedCrossRef 26.